Methods of diagnosing and treating conduct disorder

Patent metadata

Field	Value
Publication number	US-11806340-B2
Application number	US-202117511795-A
Country	US
Kind code	B2
Filing date	Oct 27, 2021
Priority date	Sep 8, 2015
Publication date	Nov 7, 2023
Grant date	Nov 7, 2023

Abstract

Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

First claim

What is claimed is:

1. A method of treating conduct disorder in a subject, comprising administering an effective amount of fasoracetam to the subject, wherein fasoracetam is administered at a dose of 50-400 mg, 100-400 mg, or 200-400 mg, and wherein the dose is administered once, twice, or three times daily.

2. The method of claim 1 , wherein the subject has at least one genetic alteration in an mGluR network gene.

3. The method of claim 2 , wherein the genetic alteration is a copy number variation (CNV) or single nucleotide variation (SNV).

4. The method of claim 3 , wherein the genetic alteration is a CNV.

5. The method of claim 4 , wherein the CNV is a duplication or deletion.

6. The method of claim 1 , wherein fasoracetam is fasoracetam monohydrate (NS-105 or NFC-1).

7. The method of claim 1 , wherein fasoracetam is administered at a dose of 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, or 400 mg.

8. The method of claim 1 , wherein the fasoracetam is administered at a dose of 200-400 mg, such as 200 mg, 300 mg, or 400 mg, and wherein the dose is administered twice daily.

9. The method of claim 4 , wherein the subject has a CNV in at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 mGluR network genes.

10. The method of claim 1 , wherein the subject does not have a CNV in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8.

11. The method of claim 1 , wherein the subject has antisocial personality disorder.

12. The method of claim 1 , wherein the subject is a pediatric, adolescent, or adult subject.

13. The method of claim 1 , wherein the fasoracetam is administered in combination with an antipsychotic agent.

14. The method of claim 1 , wherein symptoms of inattentiveness, hyperactivity, and/or impulsiveness are reduced in the subject after at least 1 week of treatment with fasoracetam.

15. The method of claim 1 , wherein symptoms of aggression or antisocial behavior are reduced in the subject after at least 1 week of treatment with fasoracetam.

16. The method of claim 1 , wherein the subject has conduct disorder as well as one or more of attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), anxiety disorder, Tourette syndrome, phobia, or depression.

17. The method of claim 1 , wherein the subject does not have any of attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), anxiety disorder, Tourette syndrome, phobia, or depression.

18. The method of claim 1 , wherein the subject has one or more of the following phenotypic changes after at least 1 week of treatment with fasoracetam:
(a) the subject has difficulty controlling anger and the anger control symptoms are improved;
(b) the subject has disruptive behaviors at the disruptive behaviors are reduced;
(c) the subject's Clinical Global Impression-Improvement (CGI-I) score is reduced by at least 1 or at least 2; the subject's CGI-I score after one, two three, or four weeks of treatment is 1 or 2;
(d) the subject's Clinical Global Impression-Severity (CGI-S) score after one, two, three, or four weeks of treatment is 1; the subject's ADHD Rating Scale score is reduced by at least 25%, such as at least 30%, at least 35%, or at least 40%;
(e) the subject has symptoms of inattentiveness and the inattentiveness symptoms are reduced; the subject has symptoms of hyperactivity and the hyperactivity symptoms are reduced;
(f) the subject has symptoms of impulsiveness and the impulsiveness symptoms are reduced;
(g) the subject has symptoms of oppositional defiant disorder (ODD), such as anger and irritability, argumentation and defiance, and/or vindictiveness, and the ODD symptoms are reduced;
(h) the subject has symptoms of anxiety and the anxiety symptoms are reduced;
(i) the subject has symptoms of Tourette's syndrome, and the Tourette's syndrome symptoms are reduced;
(j) the subject has symptoms of autism, and the autism symptoms are reduced; and
(k) the subject has symptoms of movement disorder and the movement disorder symptoms are reduced.

Assignees

• Childrens Hospital Philadelphia

Inventors

• Hakonarson Hakon
• Kao Charlly

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/454 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title